NCT05832008Completed
Increasing Adherence to Lung Cancer Screening
Increasing Equitable Adherence to Annual Lung Cancer Screening and Diagnostic Follow-up
Source: ClinicalTrials.gov · Last updated 21 Oct 2026
Brief summary (registry, in English)
Investigators are conducting a pragmatic randomized trial testing the effectiveness of patient and clinician nudge strategies on adherence to lung cancer screening (LCS) \& diagnostic follow-up across eligible primary care clinicians \& patients. Following the trial, a subsample of patients \& clinicians will be invited to one-time semi-structured interview \& survey to identify individual \& system-level factors that may restrict or enhance the impact of strategies.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 825 (actual)
- First submitted
- 23 Mar 2023
- Start date
- 18 Oct 2023
- Primary completion date
- 31 Aug 2025
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Diseases
- Lung cancer
- NCT number
- NCT05832008
What you commit to
- Study type: Interventional
- Participants enrolled: 825
- From 18 Oct 2023 to the primary completion date, 31 Aug 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Patients will be excluded if they:
- have a highly suspicious baseline LDCT (Lung-RADS 4B/X) given the presence of existing clinical pathways to ensure adherence in this group
Who the study is looking for
- Clinicians will be eligible if they:
- are practicing primary care or specialty care physicians at a recruiting site within the University of Pennsylvania Health System;
- care for patients who completed LCS via LDCT in 2019-2023; and
- do not opt-out of study participation.
- Patients will be eligible if they:
- are eligible for LCS based on 2021 US Preventive Services Task Force (USPSTF) population guidelines (aged 50-80; smoking history of 20-pack years; smoked within the last 15 years)
- completed LCS via LDCT in 2019-2023;
- have not been diagnosed with lung cancer at the time of randomization;
- meet criteria for non-adherence;
- remain eligible for LCS during the trial enrollment period; and
- receive LCS care from a clinician that has not opted-out of study participation
Age in the registry: 50 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Pennsylvania Coordinator of this site? Confirm its status | Philadelphia | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.